Cargando…
Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin
Urothelial carcinoma is a common malignancy that affects the urinary system, with bladder cancer being the most prevalent form. Although the management of early-stage disease has seen significant improvements, the treatment of locally advanced and metastatic urothelial carcinoma remains challenging....
Autores principales: | Shafique, Muhammad Ashir, Haseeb, Abdul, Siddiq, Mohammad Arham, Mussarat, Abdullah, Rangwala, Hussain Sohail, Mustafa, Muhammad Saqlain |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362867/ https://www.ncbi.nlm.nih.gov/pubmed/37485038 http://dx.doi.org/10.2147/CMAR.S418009 |
Ejemplares similares
-
Enfortumab Vedotin in urothelial cancer
por: Alt, Marie, et al.
Publicado: (2020) -
Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
por: Maiorano, Brigida Anna, et al.
Publicado: (2023) -
Advances in Polatuzumab Vedotin-PIIQ Therapy: A Review of Treatment Efficacy in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma
por: Abdur Raqib, Moosa, et al.
Publicado: (2023) -
Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date
por: Moussa, Mohamad, et al.
Publicado: (2021) -
Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma
por: Kawahara, Takashi, et al.
Publicado: (2023)